Latest Insider Transactions at International Flavors & Fragrances Inc (IFF)
This section provides a real-time view of insider transactions for International Flavors & Fragrances Inc (IFF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INTERNATIONAL FLAVORS & FRAGRANCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INTERNATIONAL FLAVORS & FRAGRANCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Open market or private sale
|
Direct |
2,588
-23.26%
|
$245,860
$95.66 P/Share
|
|
Jun 13
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
2,588
+18.87%
|
$199,276
$77.16 P/Share
|
|
May 06
2024
|
De Mendonca Ana Paula Teles President, Scent |
SELL
Payment of exercise price or tax liability
|
Direct |
262
-22.24%
|
$23,056
$88.66 P/Share
|
|
May 06
2024
|
De Mendonca Ana Paula Teles President, Scent |
BUY
Exercise of conversion of derivative security
|
Direct |
726
+38.13%
|
-
|
|
May 03
2024
|
Gaoxiang Hu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+44.25%
|
-
|
|
May 03
2024
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-9.64%
|
$65,790
$86.64 P/Share
|
|
May 03
2024
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,121
+21.09%
|
-
|
|
May 03
2024
|
Glenn R Richter CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,530
-6.99%
|
$131,580
$86.64 P/Share
|
|
May 03
2024
|
Glenn R Richter CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,243
+16.24%
|
-
|
|
May 03
2024
|
De Mendonca Ana Paula Teles President, Scent |
SELL
Payment of exercise price or tax liability
|
Direct |
255
-36.07%
|
$21,930
$86.64 P/Share
|
|
May 03
2024
|
De Mendonca Ana Paula Teles President, Scent |
BUY
Exercise of conversion of derivative security
|
Direct |
707
+50.0%
|
-
|
|
May 03
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
329
-3.71%
|
$28,294
$86.64 P/Share
|
|
May 03
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
1,060
+10.68%
|
-
|
|
May 03
2024
|
Kevin O'Byrne Director |
SELL
Payment of exercise price or tax liability
|
Direct |
218
-11.28%
|
$18,748
$86.64 P/Share
|
|
May 03
2024
|
Kevin O'Byrne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+46.37%
|
-
|
|
May 03
2024
|
Beril Yildiz CAO, SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-21.54%
|
$29,412
$86.64 P/Share
|
|
May 03
2024
|
Beril Yildiz CAO, SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
848
+34.81%
|
-
|
|
May 03
2024
|
Ralf Finzel EVP, Global Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
535
-11.22%
|
$46,010
$86.64 P/Share
|
|
May 03
2024
|
Ralf Finzel EVP, Global Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,326
+21.75%
|
-
|
|
May 03
2024
|
Christina A Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+13.36%
|
-
|
|
May 03
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
493
-4.64%
|
$42,398
$86.64 P/Share
|
|
May 03
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,591
+13.02%
|
-
|
|
May 03
2024
|
Deborah Borg EVP, Chief HR and D&I Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
713
-4.15%
|
$61,318
$86.64 P/Share
|
|
May 03
2024
|
Deborah Borg EVP, Chief HR and D&I Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,768
+9.33%
|
-
|
|
May 03
2024
|
Barry A. Bruno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+34.27%
|
-
|
|
May 03
2024
|
Mark J Costa Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+43.86%
|
-
|
|
May 03
2024
|
Carol Anthony Davidson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+46.46%
|
-
|
|
May 03
2024
|
Roger W. Ferguson Jr. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,625
+50.0%
|
-
|
|
May 03
2024
|
Yuvraj Arora President, Nourish |
SELL
Payment of exercise price or tax liability
|
Direct |
3,300
-28.6%
|
$283,800
$86.64 P/Share
|
|
May 03
2024
|
Yuvraj Arora President, Nourish |
BUY
Exercise of conversion of derivative security
|
Direct |
11,538
+50.0%
|
-
|
|
Apr 05
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
354
-2.19%
|
$29,382
$83.34 P/Share
|
|
Apr 05
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
1,140
+6.75%
|
-
|
|
Apr 05
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
494
-2.62%
|
$41,002
$83.34 P/Share
|
|
Apr 05
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,590
+7.74%
|
-
|
|
Apr 05
2024
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
350
-2.88%
|
$29,050
$83.34 P/Share
|
|
Apr 05
2024
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
968
+7.49%
|
-
|
|
Apr 01
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
461
-5.51%
|
$39,646
$86.37 P/Share
|
|
Apr 01
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,489
+15.11%
|
-
|
|
Mar 01
2024
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
81
-1.53%
|
$6,075
$75.88 P/Share
|
|
Mar 01
2024
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
195
+3.56%
|
-
|
|
Mar 01
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
104
-1.49%
|
$7,800
$75.88 P/Share
|
|
Mar 01
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Grant, award, or other acquisition
|
Direct |
286
+3.94%
|
-
|
|
Mar 01
2024
|
Frank Clyburn Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
323
-14.88%
|
$24,225
$75.88 P/Share
|
|
Mar 01
2024
|
Frank Clyburn Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,324
+37.89%
|
-
|
|
Mar 01
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-0.68%
|
$3,600
$75.88 P/Share
|
|
Mar 01
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
130
+1.81%
|
-
|
|
Mar 01
2024
|
Glenn R Richter CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-0.26%
|
$3,450
$75.88 P/Share
|
|
Mar 01
2024
|
Glenn R Richter CFO |
BUY
Grant, award, or other acquisition
|
Direct |
99
+0.56%
|
-
|
|
Jan 03
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
478
-6.44%
|
$37,762
$79.99 P/Share
|
|
Jan 03
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
1,341
+15.31%
|
-
|